Verify Mirtazapine

Drug JSON

This is exactly what your browser canonicalizes + SHA-256-hashes

{
  "slug": "mirtazapine",
  "nameEn": "Mirtazapine",
  "nameTh": "เมอร์ตาซาพีน",
  "class": "Appetite stimulant / antiemetic — tetracyclic antidepressant",
  "mechanism": "tetracyclic antidepressant ออกฤทธิ์ต้าน α2-adrenergic และ 5-HT2/5-HT3 และ H1; ในสัตว์ใช้ประโยชน์จากฤทธิ์กระตุ้นความอยากอาหารและต้านอาเจียน โดยเฉพาะในแมวโรคไตเรื้อรัง",
  "brandNamesTh": [
    "Remeron",
    "Mirataz (transdermal vet)"
  ],
  "indications": [
    {
      "text": "กระตุ้นความอยากอาหาร (appetite stimulant) และลดอาเจียนในแมวที่ผอม/เบื่ออาหาร โดยเฉพาะจาก CKD; รูปแบบ transdermal (Mirataz) ได้รับการรับรอง FDA สำหรับแมว",
      "cites": [
        "fda-mirataz"
      ]
    }
  ],
  "contraindications": [
    {
      "text": "ระวังในตับ/ไตบกพร่อง (ลดขนาด/ความถี่); ห้ามใช้ร่วมยาที่เพิ่ม serotonin (เสี่ยง serotonin syndrome); ขนาดเกินทำให้ตื่นเต้น/ส่งเสียง",
      "cites": [
        "fda-mirataz"
      ]
    }
  ],
  "sideEffects": [
    {
      "text": "ตื่นเต้น ส่งเสียงร้อง (vocalization), กระสับกระส่าย เมื่อขนาดสูง; ที่ผิวหนังบริเวณทา (transdermal) อาจระคายเคือง",
      "cites": [
        "fda-mirataz"
      ]
    }
  ],
  "dosages": [
    {
      "species": "feline",
      "indication": "Appetite stimulation (CKD / inappetence)",
      "route": "topical",
      "dose": "Mirataz transdermal 2 mg/ตัว ทาที่ใบหูชั้นใน วันละครั้ง (หรือ 1.88 mg/ตัว PO ทุก 24–48 ชม.)",
      "cites": [
        "fda-mirataz"
      ]
    }
  ],
  "citations": [
    {
      "id": "fda-mirataz",
      "type": "package-insert",
      "title": "Mirataz (mirtazapine transdermal) — FDA-approved veterinary label",
      "year": 2025,
      "url": "https://www.drugs.com/vet/mirataz.html",
      "note": "FDA veterinary label — feline appetite stimulant 2 mg/cat transdermal q24h. Public FDA labeling.",
      "cid": null
    },
    {
      "id": "dailymed-mirtazapine",
      "type": "regulatory-database",
      "title": "Mirtazapine — NLM DailyMed (FDA Structured Product Labeling)",
      "year": 2025,
      "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=mirtazapine",
      "note": "Cross-checked source: FDA-approved labeling. Search by name returns relevant product labelings.",
      "cid": "bc65c5ffc711a9f68790fcd3814828014c2d72fd7452e0d9d052392f220fefcc"
    },
    {
      "id": "atc-N06AX11",
      "type": "guideline",
      "title": "ATC N06AX11 — Mirtazapine",
      "year": 2025,
      "url": "https://www.whocc.no/atc_ddd_index/?code=N06AX11&showdescription=no",
      "note": "Cross-checked source: WHO Collaborating Centre ATC/DDD index. Authoritative drug classification.",
      "cid": "79c2c2b18074d716eff96a3fdbf8b3dbefda995518f3dd4a43b90b8a37456f97"
    },
    {
      "id": "pubchem-mirtazapine",
      "type": "monograph",
      "title": "Mirtazapine — PubChem search",
      "year": 2025,
      "url": "https://pubchem.ncbi.nlm.nih.gov/#query=Mirtazapine",
      "note": "Cross-checked source: chemical structure, identifiers, pharmacology summary. Faculty review fills exact CID.",
      "cid": "abf0390afe779287dc027c5ead37535819f5c969eb1ccab799defa214882b613"
    }
  ],
  "mirroredFrom": [
    {
      "id": "dailymed",
      "name": "NLM DailyMed",
      "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=mirtazapine",
      "asOfDate": "2026-05-27",
      "license": "U.S. Government work — public domain. Attribution recommended."
    },
    {
      "id": "atc",
      "name": "WHO ATC Classification",
      "url": "https://www.whocc.no/atc_ddd_index/?code=N06AX11&showdescription=no",
      "asOfDate": "2026-05-27",
      "license": "WHO publication, free for use with attribution"
    },
    {
      "id": "pubchem",
      "name": "PubChem (NIH/NLM)",
      "url": "https://pubchem.ncbi.nlm.nih.gov/#query=Mirtazapine",
      "asOfDate": "2026-05-27",
      "license": "NIH/NLM public domain"
    }
  ],
  "mirrorCIDs": [
    {
      "sourceId": "dailymed",
      "cid": "bc65c5ffc711a9f68790fcd3814828014c2d72fd7452e0d9d052392f220fefcc",
      "capturedAt": "2026-05-27",
      "status": "stub"
    },
    {
      "sourceId": "atc",
      "cid": "79c2c2b18074d716eff96a3fdbf8b3dbefda995518f3dd4a43b90b8a37456f97",
      "capturedAt": "2026-05-27",
      "status": "stub"
    },
    {
      "sourceId": "pubchem",
      "cid": "abf0390afe779287dc027c5ead37535819f5c969eb1ccab799defa214882b613",
      "capturedAt": "2026-05-27",
      "status": "stub"
    }
  ],
  "codes": {
    "atc": {
      "code": "N06AX11",
      "name": "Mirtazapine",
      "level": 5
    },
    "rxnorm": {
      "cui": "6929",
      "name": "Mirtazapine"
    }
  },
  "drafting": {
    "aiAssisted": false,
    "aiModel": null,
    "aiPromptHash": null,
    "humanReviewer": "palmzamak2547",
    "humanReviewedAt": "2026-05-27",
    "humanEditsRatio": null
  },
  "signatures": [],
  "reviewedBy": null,
  "lastUpdated": "2026-05-27",
  "version": 1,
  "changelog": [
    {
      "version": 0,
      "date": "2026-05-27",
      "summary": "Seed entry — cross-checked from 3 authoritative sources (NLM DailyMed, WHO ATC Classification, PubChem (NIH/NLM)). ATC N06AX11 + RxNorm 6929. Thai translation + faculty review pending."
    },
    {
      "version": 1,
      "date": "2026-05-27",
      "summary": "Clinical content compiled from cited sources — mirtazapine feline 2 mg/cat transdermal (Mirataz) / 1.88 mg PO appetite stimulation verified against FDA Mirataz label. Every statement cited. Reviewed by palmzamak2547. Pending faculty canonical signature."
    }
  ]
}

Public keys used

[]